Pricing Log in Create free account
Saturday 17 October 2026 Export NEUP’s income statement to Excel — free account

Neuphoria Therapeutics Inc.

NEUP Healthcare Biotechnology

Neuphoria Therapeutics Inc.’s revenue for fiscal 2026 (year ended June 2026) was $1.2 million, down 92.5% from fiscal 2025. In the quarter to June 2026, revenue fell 107.3%, EPS grew 83.6% and free cash flow grew 133.9%, each against the same quarter a year earlier.

3.30 0.01 −0.30%
Market cap
$17.9M
P/E
0.0×
Fwd P/E
−1.9×
Dividend yield
—
F-score
n/a
Altman Z
−7.55
Beneish M
831.96
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 17.91
Revenue 15.66
Net Income (13.45)
Free Cash Flow (12.35)
Net Debt (19.87)
Current Ratio 27.85 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (1.85) (negative: loss-making)
P/S ratio 0.91
P/B ratio 0.58
Past 5Y EPS Growth —
This Y EPS Growth 40.29% (at or above 15%: strong)
Next Y EPS Growth (1.23%) (below 0%: weak)
Next Y revenue growth 788.06% (at or above 10%: strong)
Next 5Y EPS Growth (13.71%) (below 0%: weak)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −0.3×, against a ten-year median of 1.5×; over the ten years it ranged from −14.1× in 2024 to 1,672× in 2022.
P/S against its own 10 years 12.70%
10-year low 10-year high
P/B against its own 10 years 29.10%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —

Assets vs Liabilities $m

2023 2024 2025 2026
Cash 12 13 14 20
Receivables 0 0 0 1
Inventory — — — —
Other — — — —
13 13 15 21
2023 2024 2025 2026
Payables 1 2 1 0
ST’ Debt — — — —
Other — — — —
3 4 4 1

Compound Annual Growth %

10y 5y 3y
Sales — 19.07% 83.09%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — (7.11%) 3.78%

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’26 — — — — 1
’25 15 0 — 1 16
’23 — 0 — — 0
’22 — 0 — 0 0
’20 — 0 — 0 0
’19 — 1 — — 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Sep Dec Mar Jun Year
’26 — — — — —
’26 (4) (6) (3) 1 (12)
’25 (4) (3) 11 (4) 0
’24 (4) (5) (2) (3) (15)
’23 — (6) — (14) (15)
’22 — (9) — (16) (16)
’21 — (1) — (6) (6)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Sep Dec Mar Jun Year
’26 — — — — —
’26 (4) (6) (3) 1 (12)
’25 (4) (3) 11 (4) 0
’24 (4) (5) (2) (3) (15)
’23 — (6) — (14) (15)
’22 — (9) — (16) (16)
’21 — (1) — (6) (6)
Fiscal quarters ending in the months shown.

EPS $

Sep Dec Mar Jun Year
’26 — — — — —
’26 (4.41) 0.41 (0.09) (0.95) (3.06)
’25 (0.62) (1.23) 6.55 (5.79) (0.23)
’24 (7.90) — (2.83) (2.57) (18.61)
’23 — (0.01) — (0.01) (29.05)
’22 — (0.01) — (0.01) (31.33)
’21 — 0.00 — (0.01) (18.00)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to June

Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Trend 2027e 2028e 2029e
Price, $
Price, $ Low — — — — 144.60 51.00 11.16 2.12 2.90 3.19

Analyst estimates 2027–2029

Powerpack
High — — — — 264.00 165.12 92.52 18.00 21.40 5.53
People
People Employees — — — — 7 7 8 8 8 1
Revenue/emp, $m 0.00 0.00 0.00 0.00 0.00 0.03 0.00 0.00 1.96 1.17
Income, $m
Income, $m Revenue 14 3 0 0 — 0 0 — 16 1
Gross margin, % 0.00 0.00 0.00 0.00 0.00 100.00 100.00 — 100.00 100.00
EBT (10) (24) (12) (6) (7) (16) (22) (16) (1) (14)
EBT margin, % (71.15) (874.26) (2,428.24) (19,212.42) 0.00 (8,324.93) (145,411.49) 0.00 (5.35) (1,157.48)
Net income 0 (19) (7) (4) (6) (16) (21) (15) 0 (13)
Depreciation 1 1 1 2 1 1 1 1 1 1
Per share, $
Per share, $ Revenue 4.47 0.90 0.15 0.01 0.00 0.31 0.02 0.00 9.64 0.27
Earnings (0.01) (0.03) (0.01) (0.01) (13.93) (31.33) (29.05) (18.61) (0.23) (3.06)
Cash flow (0.06) (4.79) (3.22) (0.76) (15.61) (25.20) (21.54) (17.64) 0.05 (2.81)
Capex 0.00 0.00 0.00 0.00 0.07 0.20 0.00 0.00 0.00 0.00
Free cash flow (0.06) (4.79) (3.22) (0.76) (15.54) (25.00) (21.54) (17.64) 0.05 (2.81)
Book value 9.81 4.08 3.47 2.50 98.55 65.93 32.38 21.02 11.71 5.60
Shares, m 3 3 3 3 0 1 1 1 2 4
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 — 0.00 0.00 — 0.00 0.00
P/S 558.54 558.54 558.54 558.54 — 1,463.61 574.69 — 0.74 1.23
P/B 21.54 21.54 21.54 21.54 — 15.27 0.00 — 0.61 0.78
EV/Sales 543.25 543.25 543.25 543.25 — 1,408.25 543.36 — (0.12) 0.02
EV/FCF (80.32) (80.32) (80.32) (80.32) — (19.13) (4.49) — (8.12) (0.02)
Cash, $m
Cash, $m Operating cash flow 0 (15) (11) (3) (6) (16) (15) (15) 0 (12)
Capex 0 0 0 0 0 0 — — — —
Free cash flow 0 (15) (11) (3) (6) (16) (15) (15) 0 (12)
Balance, $m
Balance, $m Working capital 31 17 8 0 21 28 11 9 11 20
Total debt 14 16 13 8 1 0 0 — — —
Net debt (19) (3) 3 5 (21) (24) (12) (13) (14) (20)
Shareholders’ equity 31 13 12 9 36 41 22 17 19 25
Returns, %
Returns, % ROA (9.20) (77.11) (16.91) (15.95) (20.26) (35.91) (56.31) (55.12) (1.31) (46.95)
ROIC 0.00 0.00 0.00 0.00 (24.03) (57.33) (138.68) (229.05) (14.97) (217.17)
ROE (23.77) (85.08) (60.13) (48.22) (29.37) (41.08) (67.56) (78.44) (2.03) (61.70)
Negative figures in brackets.

All 10 years →

Fiscal years to Jun 2026 · latest quarter Jun 2025 · fundamentals updated 2 Oct 2026

Charts ten years each

Neuphoria Therapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ATYR aTyr Pharma, Inc. $18.0M — (loss-making) — (loss-making) −90.75% (below 0%: shrinking) n/m +32.22% (above 0%: growing) 100.00% 0.00% Compare
NEUP Neuphoria Therapeutics Inc. $17.9M — (loss-making) — (loss-making) −107.32% (below 0%: shrinking) n/m +133.86% (above 0%: growing) 100.00% 0.00%
JSPR Jasper Therapeutics, Inc. $17.7M — (loss-making) — — n/m +55.74% (above 0%: growing) 0.00% 0.00% Compare
ANEB Anebulo Pharmaceuticals, Inc. $17.6M — (loss-making) — — n/m +6.58% (above 0%: growing) — 0.00% Compare
ACGN Aceragen, Inc. $17.1M — (loss-making) — (loss-making) +2,394.95% (above 0%: growing) n/m −115.67% (below 0%: shrinking) 100.00% (834.33%) Compare
RADX Radiopharm Theranostics Limited - Sponsored ADR $17.0M — — — — −137.75% (below 0%: shrinking) — — Compare
DYAI Dyadic International Inc. $16.8M — (loss-making) — (loss-making) −0.57% (below 0%: shrinking) n/m −1,298.54% (below 0%: shrinking) (2.39%) (213.73%) Compare
PBM Psyence Biomedical Ltd. $16.5M 0.2× — — n/m −707.20% (below 0%: shrinking) — 0.00% Compare
TCRX TScan Therapeutics, Inc. $16.2M — (loss-making) — (loss-making) −65.83% (below 0%: shrinking) n/m +18.95% (above 0%: growing) 100.00% (2,901.33%) Compare
Median of peers $17.1M — — −33.20% — −54.54% 100.00% 0.00%

All 614 Biotechnology stocks →

Neuphoria Therapeutics Inc. (NEUP) key facts

  • Concern: Neuphoria Therapeutics Inc.’s revenue for fiscal 2026 (year ended June 2026) was $1.2 million, down 92.5% from fiscal 2025.
  • Neuphoria Therapeutics Inc. (NEUP) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
  • As of October 16, 2026, NEUP traded at $3.30, a market capitalization of $17.9 million.
  • Return on equity was −61.7% and debt-to-equity 0.00.
  • Its Altman Z-score is −7.55 (distress zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Oct 2, 2026.

Neuphoria Therapeutics Inc. (NEUP) Latest News

23 Jul

Impact 5 ·
Impact 5 ·
Impact 5 ·
stockrow.com/NEUP · Data as of Oct 2, 2026 · For information only; not investment advice. · © 2026 stockrow.com